- Home
- NGD vs FOLD Comparison
NGD vs FOLD Comparison
Compare NGD & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGD | FOLD |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 2002 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NGD | FOLD |
|---|---|---|
| Price | $11.20 | $14.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $11.13 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 14.6M | 3.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $61.06 | $20.50 |
| Revenue Next Year | $62.93 | $18.59 |
| P/E Ratio | $35.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.73 | $5.66 |
| 52 Week High | $13.63 | $14.38 |
Technical Indicators
Market Signals| Indicator | NGD | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 66.13 |
| Support Level | $9.80 | $14.21 |
| Resistance Level | $13.58 | $14.37 |
| Average True Range (ATR) | 0.71 | 0.03 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 30.81 | 42.86 |
Price Performance
Historical ComparisonAbout NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.